Pharmaceutical Research

, Volume 27, Issue 3, pp 457–467

Cell-Based Multiscale Computational Modeling of Small Molecule Absorption and Retention in the Lungs

Research Paper

Abstract

Purpose

For optimizing the local, pulmonary targeting of inhaled medications, it is important to analyze the relationship between the physicochemical properties of small molecules and their absorption, retention and distribution in the various cell types of the airways and alveoli.

Methods

A computational, multiscale, cell-based model was constructed to facilitate analysis of pulmonary drug transport and distribution. The relationship between the physicochemical properties and pharmacokinetic profile of monobasic molecules was explored. Experimental absorption data of compounds with diverse structures were used to validate this model. Simulations were performed to evaluate the effect of active transport and organelle sequestration on the absorption kinetics of compounds.

Results

Relating the physicochemical properties to the pharmacokinetic profiles of small molecules reveals how the absorption half-life and distribution of compounds are expected to vary in different cell types and anatomical regions of the lung. Based on logP, pKa and molecular radius, the absorption rate constants (Ka) calculated with the model were consistent with experimental measurements of pulmonary drug absorption.

Conclusions

The cell-based mechanistic model developed herein is an important step towards the rational design of local, lung-targeted medications, facilitating the design and interpretation of experiments aimed at optimizing drug transport properties in lung.

KEY WORDS

computational modeling drug absorption drug delivery drug targeting lung pharmacokinetics physicochemical properties 

Supplementary material

11095_2009_34_MOESM1_ESM.doc (860 kb)
ESM 1(DOC 860 kb)

REFERENCES

  1. 1.
    Brewis RL, Corrin B, Geddes DM, Gibson GJ, editors. Respiratory medicine. London: WB Saunders; 1995.Google Scholar
  2. 2.
    Ehrhardt C, Kim K-J, editors. Drug absorption studies: in situ, in vitro and in silico models. Arlington: Springer; 2008.Google Scholar
  3. 3.
    Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42:697–705.CrossRefPubMedGoogle Scholar
  4. 4.
    Wall DA, Lanutti AT. High-levels of exopeptidase activity are present in rat and canine bronchoalveolar lavage fluid. Int J Pharm. 1993;97:171–81.CrossRefGoogle Scholar
  5. 5.
    Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliver Rev. 1996;19:3–36.CrossRefGoogle Scholar
  6. 6.
    Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, et al. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Resp Cell Mol. 1997;16:242–9.Google Scholar
  7. 7.
    Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug. 1995;12:151–231.Google Scholar
  8. 8.
    LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine. 1999;17:1796–803.CrossRefPubMedGoogle Scholar
  9. 9.
    Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, et al. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost. 2001;85:445–9.PubMedGoogle Scholar
  10. 10.
    Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.CrossRefGoogle Scholar
  12. 12.
    Gumbleton M, Taylor G. Challenges and innovations in effective pulmonary systemic and macromolecular drug delivery. Adv Drug Deliv Rev. 2006;58:993–5.CrossRefGoogle Scholar
  13. 13.
    Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009–29.CrossRefPubMedGoogle Scholar
  14. 14.
    Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliver Rev. 1996;19:359–76.CrossRefGoogle Scholar
  15. 15.
    Egan WJ, Lauri G. Prediction of intestinal permeability. Adv Drug Deliver Rev. 2002;54:273–89.CrossRefGoogle Scholar
  16. 16.
    Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliver Rev. 2002;54:291–313.CrossRefGoogle Scholar
  17. 17.
    Brown RA, Schanker LS. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos. 1983;11:355–60.Google Scholar
  18. 18.
    Schanker LS, Hemberger JA. Relation between molecular-weight and pulmonary absorption rate of lipid-insoluble compounds in neonatal and adult-rats. Biochem Pharmacol. 1983;32:2599–601.CrossRefGoogle Scholar
  19. 19.
    Schanker LS, Mitchell EW, Brown RA. Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos. 1986;14:79–88.PubMedGoogle Scholar
  20. 20.
    Effros RM, Pornsuriyasak P, Porszasz J, Casaburi R. Indicator dilution measurements of extravascular lung water: basic assumptions and observations. Am J Physiol Lung Cell Mol Physiol. 2008;294:L1023–1031.CrossRefPubMedGoogle Scholar
  21. 21.
    Effros RM. Exhaled breath condensates and COPD. Eur Respir J. 2009;33:1238.CrossRefPubMedGoogle Scholar
  22. 22.
    Tronde A. Pulmonary drug absorption: in vitro and in vivo investigations of drug absorption across the lung barrier and its relation to drug physicochemical properties, Faculty of Pharmacy, Vol. Ph.D. Uppsala University; 2002.Google Scholar
  23. 23.
    Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, et al. Drug absorption from the isolated perfused rat lung—correlations with drug physicochemical properties and epithelial permeability. J Drug Target. 2003;11:61–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure–absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci. 2003;92:1216–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Manford F, Tronde A, Jeppsson AB, Patel N, Johansson F, Forbes B. Drug permeability in 16HBE14o—airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sci. 2005;26:414–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Oprea TI. Chemical space navigation in lead discovery. Curr Opin Chem Biol. 2002;6:384–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhang X, Shedden K, Rosania GR. A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharmaceut. 2006;3:704–16.CrossRefGoogle Scholar
  28. 28.
    Zhang X, Zheng N, Rosania GR. Simulation-based cheminformatic analysis of organelle-targeted molecules: lysosomotropic monobasic amines. J Comput Aided Mol Des. 2008;22:629–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Trapp S, Horobin RW. A predictive model for the selective accumulation of chemicals in tumor cells. Eur Biophys J. 2005;34:959–66.Google Scholar
  30. 30.
    Balon K, Riebesehl BU, Muller BW. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm Res. 1999;16:882–8.Google Scholar
  31. 31.
    Parent RA, editor. Treatise on pulmonary toxicology: comparative biology of the normal lung. Boca Raton: CRC; 1992.Google Scholar
  32. 32.
    Widdicombe JG. Airway liquid: a barrier to drug diffusion? Eur Respir J. 1997;10:2194–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Salmon M, Walsh DA, Huang TJ, Barnes PJ, Leonard TB, Hay DW, et al. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol. 1999;127:1151–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Cohen MD, Zelikoff JT, Schlesinger RB, editors. Pulmonary immunotoxicology. New York: Springer; 2000.Google Scholar
  35. 35.
    Crane GJ, Kotecha N, Luff SE, Neil TO. Electrical coupling between smooth muscle and endothelium in arterioles of the guinea-pig small intestine. Phys Med Biol. 2001;46:2421–34.CrossRefPubMedGoogle Scholar
  36. 36.
    James AL, Bai TR, Mauad T, Abramson MJ, Dolhnikoff M, McKay KO, et al. Airway smooth muscle thickness in asthma is related to severity but not duration of asthma. Eur Respir J. 2009;34(5):1040–45.Google Scholar
  37. 37.
    Yeh HC, Schum GM, Duggan MT. Anatomic models of the tracheobronchial and pulmonary regions of the rat. Anat Rec. 1979;195:483–92.CrossRefPubMedGoogle Scholar
  38. 38.
    Miller LA, Hurst SD, Coffman RL, Tyler NK, Stovall MY, Chou DL, et al. Airway generation-specific differences in the spatial distribution of immune cells and cytokines in allergen-challenged rhesus monkeys. Clin Exp Allergy. 2005;35:894–906.CrossRefPubMedGoogle Scholar
  39. 39.
    Ross MH, Pawlina W, editors. Histology: a text and Atlas: with correlated cell and molecular biology. Baltimore: Lippincott Williams & Wilkins; 2006.Google Scholar
  40. 40.
    Kroll F, Karlsson JA, Persson CG. Tracheobronchial microvessels perfused via the pulmonary artery in guinea-pig isolated lungs. Acta Physiol Scand. 1987;129:445–6.PubMedGoogle Scholar
  41. 41.
    Sims DE, Horne MM. Heterogeneity of the composition and thickness of tracheal mucus in rats. Am J Physiol. 1997;273:L1036–1041.Google Scholar
  42. 42.
    Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta. 1998;1408:90–108.PubMedGoogle Scholar
  43. 43.
    Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci. 1999;88:1067–72.CrossRefPubMedGoogle Scholar
  44. 44.
    Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003;20:1200–9.CrossRefGoogle Scholar
  45. 45.
    Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res. 2006;23:1712–20.CrossRefPubMedGoogle Scholar
  46. 46.
    Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008;97:553–65.CrossRefPubMedGoogle Scholar
  47. 47.
    Frenchand MC, Wishart GN. Isolated perfused rabbit lung as a model to study the absorption of organic aerosols. J Pharmacol Method. 1985;13:241–8.CrossRefGoogle Scholar
  48. 48.
    Hamilton KO, Backstrom G, Yazdanian MA, Audus KL. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J Pharm Sci. 2001;90:647–58.CrossRefPubMedGoogle Scholar
  49. 49.
    Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001;298:1199–205.PubMedGoogle Scholar
  50. 50.
    Endter S, Francombe D, Ehrhardt C, Gumbleton M. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol. 2009;61:583–91.CrossRefPubMedGoogle Scholar
  51. 51.
    Wagner D, Glube N, Berntsen N, Tremel W, Langguth P. Different dissolution media lead to different crystal structures of talinolol with impact on its dissolution and solubility. Drug Dev Ind Pharm. 2003;29:891–902.CrossRefPubMedGoogle Scholar
  52. 52.
    Marvin and Calculator, ChemAxon, Budapest, Hungary, 2007.Google Scholar
  53. 53.
    Petitjean M. Applications of the radius diameter diagram to the classification of topological and geometrical shapes of chemical-compounds. J Chem Inf Comp Sci. 1992;32:331–7.Google Scholar
  54. 54.
    MOE: Molecular Operating Environment, Chemical Computing Group, Montreal, Quebec, Canada, 2007.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medicinal Chemistry, College of PharmacyUniversity of MichiganAnn ArborUSA
  2. 2.Department of Pharmaceutical Science, College of PharmacyUniversity of MichiganAnn ArborUSA

Personalised recommendations